- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: Dichloroacetic acid, bichloroacetic acid, BCA 中文名稱:二氯乙酸鈉
DCA (Sodium dichloroacetate)是 pyruvate dehydrogenase kinase (PDK) 的特異性抑制劑,對PDK2和PDK4的IC50值分別為183和80 μM;可抑制 Na+-K+-2Cl- cotransporter 和線粒體鉀離子通道軸。Sodium dichloroacetate 可增加活性氧的生成,引起癌細胞凋亡,并抑制腫瘤生長。
DCA (Sodium dichloroacetate) Chemical Structure
CAS: 2156-56-1
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
MCF7 | Function assay | 10 mM | 12 hrs | Inhibition of PDK1 in human MCF7 cells assessed as increase in oxygen consumption rate at 10 mM after 12 hrs | 27006991 |
MCF7 | Function assay | 10 mM | 12 hrs | Inhibition of PDK1 in human MCF7 cells assessed as decrease in extracellular acidification rate at 10 mM after 12 hrs | 27006991 |
MCF7 | Function assay | 10 mM | 12 hrs | Inhibition of PDK1 in human MCF7 cells assessed as decrease in proton production rate at 10 mM after 12 hrs | 27006991 |
MCF7 | Function assay | 10 mM | 12 hrs | Inhibition of PDK1 in human MCF7 cells assessed as increase in ratio of oxygen consumption rate to extracellular acidification rate at 10 mM after 12 hrs | 27006991 |
MCF7 | Function assay | 10 mM | 12 hrs | Inhibition of PDK1 in human MCF7 cells assessed as decrease in lactate production at 10 mM after 12 hrs | 27006991 |
NCI-H1975 | Antiproliferative assay | 20 mM | 72 hrs | Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability at 20 mM after 72 hrs by MTT assay | 30470491 |
MCF7 | Antitumor assay | 30 mg/kg | two weeks | Antitumor activity against human MCF7 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered every two days for two weeks measured after 14 days | 31509699 |
MCF7 | Function assay | 30 uM | 4 hrs | Induction of metabolic reversal from aerobic glycolysis to oxidative phosphorylation in human MCF7 cells assessed as increase in extracellular acidification rate at 30 uM pretreated for 4 hrs followed by glucose addition after 25 mins by seahorse XF24 ext | 31509699 |
MCF7 | Function assay | 30 uM | 4 hrs | Induction of metabolic reversal from aerobic glycolysis to oxidative phosphorylation in human MCF7 cells assessed as increase in extracellular acidification rate at 30 uM pretreated for 4 hrs followed by glucose addition after 25 mins followed by subsequent assay | 31509699 |
MCF7 | Function assay | 30 uM | 4 hrs | Induction of metabolic reversal from aerobic glycolysis to oxidative phosphorylation in human MCF7 cells assessed as decline in extracellular acidification rate at 30 uM pretreated for 4 hrs followed by glucose addition after 25 mins followed by subsequent assay | 31509699 |
MCF7 | Function assay | 30 uM | 6 hrs | Induction of metabolic reversal from aerobic glycolysis to oxidative phosphorylation in human MCF7 cells assessed as decrease in oxygen consumption rate at 30 uM pretreated for 6 hrs followed by oligomycin A addition after 25 mins followed by subsequent assay | 31509699 |
MCF7 | Function assay | 90 mins | Inhibition of PDK1 (unknown origin) expressed in human MCF7 cells using PDK tide as substrate measured after 90 mins in presence of ATP by ADP-Glo luminescent kinase assay | 31509699 | |
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | DCA (Sodium dichloroacetate)是 pyruvate dehydrogenase kinase (PDK) 的特異性抑制劑,對PDK2和PDK4的IC50值分別為183和80 μM;可抑制 Na+-K+-2Cl- cotransporter 和線粒體鉀離子通道軸。Sodium dichloroacetate 可增加活性氧的生成,引起癌細胞凋亡,并抑制腫瘤生長。 | ||||
---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | DCA可引起人類肺部、乳腺和腦癌細胞的凋亡[1]。經(jīng)DCA處理后,癌細胞中的ROS水平升高、MMP去極化、在體內(nèi)外都能夠增加凋亡[2]。DCA抑制丙酮酸脫氫酶激酶(PDK)的活性,因而刺激線粒體丙酮酸脫氫酶(PDH)。當PDH處于關(guān)閉狀態(tài)時,PDH不再將丙酮酸轉(zhuǎn)化為acetyl-CoA(線粒體呼吸和葡萄糖依賴的氧化磷酸化過程所必需)。從而,DCA將細胞代謝從糖酵解轉(zhuǎn)換為葡萄糖氧化,降低線粒體膜電位,促進線粒體轉(zhuǎn)運孔的開放。這一系列代謝轉(zhuǎn)換有助于促凋亡介質(zhì)如cyt c和AIF的易位。因而,DCA可通過凋亡反應驅(qū)動癌細胞自殺[3]。 | |||
---|---|---|---|---|
細胞實驗 | 細胞系 | 乳腺癌細胞 | ||
濃度 | 5 mM | |||
孵育時間 | 24-72 h | |||
方法 | 將細胞以3000細胞/孔的密度鋪于96孔板。用DCA和ATO處理24-72小時,然后換成新鮮的含30 μg/ml的中性紅培養(yǎng)基孵育3小時。PBS洗滌細胞,加入lysis buffer(acetic acid/methanol, 80%/20%),在540 nm處檢測吸光值。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | pPDH E1α / PDH E1α |
![]() |
25630799 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | DCA在體內(nèi)體外可作為細胞生長抑制劑,而不引起程序性細胞死亡(凋亡)。DCA是一種安全性較高的藥物,沒有心臟、肺部、腎臟或骨髓毒性。最為嚴重的副作用包括周圍神經(jīng)病變,該作用為可逆過程。DCA在好幾種癌癥類型中,包括結(jié)腸癌、前列腺癌、卵巢癌、成神經(jīng)細胞瘤、肺癌、子宮頸癌、子宮內(nèi)膜、膽管癌、肉瘤和T細胞淋巴瘤具有抗癌活性。DCA的其他一些抗腫瘤作用也被報導,包括阻礙血管生成、改變HIF-1α的表達、pH調(diào)節(jié)劑V-ATPase和MCT1的改變、其他細胞生存調(diào)節(jié)子如PUMA、GLUT1、Bcl2和p53的改變。在大鼠高轉(zhuǎn)移乳腺癌模型中,DCA能夠顯著地減少肺部轉(zhuǎn)移性負擔[1]。在C57BL/6小鼠中,DCA-Na的體內(nèi)給藥可誘導20%的生存率提高并減少腫瘤直徑、體積和重量,而不影響其體重、并避免轉(zhuǎn)移[3]。 | |
---|---|---|
動物實驗 | Animal Models | C57BL/6 mice |
Dosages | 500 and 1000 mg/kg | |
Administration | i.p. |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT06073106 | Not yet recruiting | Stroke|Traumatic Brain Injury|Knee Osteoarthritis|Breast Cancer |
Tan Tock Seng Hospital|Rehabilitation Research Institute of Singapore (RRIS)|Woodlands Health (WH) |
December 2023 | -- |
NCT05810623 | Not yet recruiting | Upper Urinary Tract Urothelial Carcinoma|Bladder Cancer |
David D''Andrea|Medical University of Vienna |
June 1 2023 | Phase 3 |
NCT05646485 | Recruiting | Bladder Cancer|Urothelial Carcinoma|Hematuria|Smoking Cessation |
University of Texas Southwestern Medical Center |
May 5 2023 | Not Applicable |
NCT05460533 | Recruiting | B-cell Acute Lymphoblastic Leukemia |
Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals |
July 12 2022 | Phase 2 |
分子量 | 150.92 | 分子式 | C2HCl2O2.Na |
CAS號 | 2156-56-1 | SDF | Download DCA (Sodium dichloroacetate) SDF |
Smiles | C(C(=O)[O-])(Cl)Cl.[Na+] | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
|
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項